Cargando…
ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study
BACKGROUND: Blood-based biomarkers for Alzheimer’s disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for larg...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792035/ https://www.ncbi.nlm.nih.gov/pubmed/33419480 http://dx.doi.org/10.1186/s13195-020-00750-y |
_version_ | 1783633719566794752 |
---|---|
author | Oliveira Monteiro, Maria Patrícia A. Salheb Oliveira, Danielle S. M. Manzine, Patrícia R. Crispim Nascimento, Carla M. dos Santos Orlandi, Ariene A. de Oliveira Gomes, Grace A. dos Santos Orlandi, Fabiana Zazzetta, Marisa S. Pott-Junior, Henrique Cominetti, Marcia R. |
author_facet | Oliveira Monteiro, Maria Patrícia A. Salheb Oliveira, Danielle S. M. Manzine, Patrícia R. Crispim Nascimento, Carla M. dos Santos Orlandi, Ariene A. de Oliveira Gomes, Grace A. dos Santos Orlandi, Fabiana Zazzetta, Marisa S. Pott-Junior, Henrique Cominetti, Marcia R. |
author_sort | Oliveira Monteiro, Maria Patrícia A. |
collection | PubMed |
description | BACKGROUND: Blood-based biomarkers for Alzheimer’s disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Blood-based biomarkers allow an initial large-scale screening of patients under suspicion that could later be tested for the already established CSF biomarkers. To this regard, in this study, we evaluated whether plasma ADAM10 levels would be predictors of declines in cognition in community-dwelling older adults after a 3-year period follow-up. METHODS: This was a 3-year longitudinal cohort study that included 219 community-dwelling older adults. Sociodemographic, clinical, lifestyle, depressive symptoms (GDS), and cognitive data (Mini-Mental State Examination, MMSE; Clock Drawing test, CDT) were gathered. The measurement of ADAM10 plasma levels was performed using a sandwich ELISA kit. Bivariate comparisons between groups were performed using Wilcoxon-Mann-Whitney for continuous data and Pearson’s chi-square tests with Yates continuity correction for categorical data. Longitudinal analyzes of changes in the MMSE scores were performed using linear mixed-effects modeling. RESULTS: Baseline MMSE scores and ADAM10 levels were significantly associated with MMSE scores on the follow-up assessment. When analyzing the interaction with time, normal MMSE scores and the ADAM10 plasma levels at baseline presented a significant and independent negative association with MMSE score values on the follow-up assessment. The analyses also showed that the predictive effect of ADAM10 plasma levels on decreasing MMSE scores on follow-up seems to be more pronounced in participants with normal MMSE, when compared with those with altered MMSE scores at baseline. CONCLUSIONS: Considering that ADAM10 increase in plasma is detected as soon as in mild cognitive impairment (MCI) patients, the results presented here may support the complementary clinical use of this biomarker, in addition to the classical AD biomarkers. Taken together, these results provide the first direct evidence that changes in ADAM10 plasma levels are predictors of cognitive worsening in older adults. Moreover, this work can shed light on the study of blood biomarkers for AD and contribute to the advancement of the area. |
format | Online Article Text |
id | pubmed-7792035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77920352021-01-11 ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study Oliveira Monteiro, Maria Patrícia A. Salheb Oliveira, Danielle S. M. Manzine, Patrícia R. Crispim Nascimento, Carla M. dos Santos Orlandi, Ariene A. de Oliveira Gomes, Grace A. dos Santos Orlandi, Fabiana Zazzetta, Marisa S. Pott-Junior, Henrique Cominetti, Marcia R. Alzheimers Res Ther Research BACKGROUND: Blood-based biomarkers for Alzheimer’s disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Blood-based biomarkers allow an initial large-scale screening of patients under suspicion that could later be tested for the already established CSF biomarkers. To this regard, in this study, we evaluated whether plasma ADAM10 levels would be predictors of declines in cognition in community-dwelling older adults after a 3-year period follow-up. METHODS: This was a 3-year longitudinal cohort study that included 219 community-dwelling older adults. Sociodemographic, clinical, lifestyle, depressive symptoms (GDS), and cognitive data (Mini-Mental State Examination, MMSE; Clock Drawing test, CDT) were gathered. The measurement of ADAM10 plasma levels was performed using a sandwich ELISA kit. Bivariate comparisons between groups were performed using Wilcoxon-Mann-Whitney for continuous data and Pearson’s chi-square tests with Yates continuity correction for categorical data. Longitudinal analyzes of changes in the MMSE scores were performed using linear mixed-effects modeling. RESULTS: Baseline MMSE scores and ADAM10 levels were significantly associated with MMSE scores on the follow-up assessment. When analyzing the interaction with time, normal MMSE scores and the ADAM10 plasma levels at baseline presented a significant and independent negative association with MMSE score values on the follow-up assessment. The analyses also showed that the predictive effect of ADAM10 plasma levels on decreasing MMSE scores on follow-up seems to be more pronounced in participants with normal MMSE, when compared with those with altered MMSE scores at baseline. CONCLUSIONS: Considering that ADAM10 increase in plasma is detected as soon as in mild cognitive impairment (MCI) patients, the results presented here may support the complementary clinical use of this biomarker, in addition to the classical AD biomarkers. Taken together, these results provide the first direct evidence that changes in ADAM10 plasma levels are predictors of cognitive worsening in older adults. Moreover, this work can shed light on the study of blood biomarkers for AD and contribute to the advancement of the area. BioMed Central 2021-01-08 /pmc/articles/PMC7792035/ /pubmed/33419480 http://dx.doi.org/10.1186/s13195-020-00750-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Oliveira Monteiro, Maria Patrícia A. Salheb Oliveira, Danielle S. M. Manzine, Patrícia R. Crispim Nascimento, Carla M. dos Santos Orlandi, Ariene A. de Oliveira Gomes, Grace A. dos Santos Orlandi, Fabiana Zazzetta, Marisa S. Pott-Junior, Henrique Cominetti, Marcia R. ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title | ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title_full | ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title_fullStr | ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title_full_unstemmed | ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title_short | ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
title_sort | adam10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792035/ https://www.ncbi.nlm.nih.gov/pubmed/33419480 http://dx.doi.org/10.1186/s13195-020-00750-y |
work_keys_str_mv | AT oliveiramonteiromariapatriciaa adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT salheboliveiradaniellesm adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT manzinepatriciar adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT crispimnascimentocarlam adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT dossantosorlandiarienea adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT deoliveiragomesgracea adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT dossantosorlandifabiana adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT zazzettamarisas adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT pottjuniorhenrique adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy AT cominettimarciar adam10plasmalevelspredictworseningincognitionofolderadultsa3yearfollowupstudy |